These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
503 related articles for article (PubMed ID: 33428889)
1. YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Szulzewsky F; Holland EC; Vasioukhin V Dev Biol; 2021 Jul; 475():205-221. PubMed ID: 33428889 [TBL] [Abstract][Full Text] [Related]
2. Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer. Yang P; Li Y; Hou J; Wu D; Zeng X; Zeng Z; Zhang J; Xiong Y; Chen L; Yang D; Wan X; Wu Z; Jia L; Liu Q; Lu Q; Zou X; Fang W; Zeng X; Zhou D J Biol Chem; 2024 Jun; 300(6):107309. PubMed ID: 38657867 [TBL] [Abstract][Full Text] [Related]
3. Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis. Szulzewsky F; Arora S; Hoellerbauer P; King C; Nathan E; Chan M; Cimino PJ; Ozawa T; Kawauchi D; Pajtler KW; Gilbertson RJ; Paddison PJ; Vasioukhin V; Gujral TS; Holland EC Genes Dev; 2020 Aug; 34(15-16):1051-1064. PubMed ID: 32675324 [TBL] [Abstract][Full Text] [Related]
4. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine. Nagashima S; Bao Y; Hata Y Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663 [TBL] [Abstract][Full Text] [Related]
5. Effects of the hippo signaling pathway in human gastric cancer. Zhou GX; Li XY; Zhang Q; Zhao K; Zhang CP; Xue CH; Yang K; Tian ZB Asian Pac J Cancer Prev; 2013; 14(9):5199-205. PubMed ID: 24175801 [TBL] [Abstract][Full Text] [Related]
6. NEDD8 enhances Hippo signaling by mediating YAP1 neddylation. Chen M; Liu Y; Zuo M; Guo C; Du Y; Xu H; Liu B; Li M; Xiao W; Yu G J Biol Chem; 2024 Aug; 300(8):107512. PubMed ID: 38960037 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome. Rybarczyk A; Klacz J; Wronska A; Matuszewski M; Kmiec Z; Wierzbicki PM Oncol Rep; 2017 Jul; 38(1):427-439. PubMed ID: 28504812 [TBL] [Abstract][Full Text] [Related]
8. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. Sekine S; Kiyono T; Ryo E; Ogawa R; Wakai S; Ichikawa H; Suzuki K; Arai S; Tsuta K; Ishida M; Sasajima Y; Goshima N; Yamazaki N; Mori T J Clin Invest; 2019 May; 129(9):3827-3832. PubMed ID: 31145701 [TBL] [Abstract][Full Text] [Related]
9. Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. Kang W; Cheng AS; Yu J; To KF World J Gastroenterol; 2016 Jan; 22(3):1279-88. PubMed ID: 26811664 [TBL] [Abstract][Full Text] [Related]
10. YAP1 and PRDM14 converge to promote cell survival and tumorigenesis. Kim M; Ly SH; Xie Y; Duronio GN; Ford-Roshon D; Hwang JH; Sulahian R; Rennhack JP; So J; Gjoerup O; Talamas JA; Grandclaudon M; Long HW; Doench JG; Sethi NS; Giannakis M; Hahn WC Dev Cell; 2022 Jan; 57(2):212-227.e8. PubMed ID: 34990589 [TBL] [Abstract][Full Text] [Related]
11. The role of Hippo/YAP1 in cancer-associated fibroblasts: Literature review and future perspectives. Athavale D; Balch C; Zhang Y; Yao X; Song S Cancer Lett; 2024 Nov; 604():217244. PubMed ID: 39260668 [TBL] [Abstract][Full Text] [Related]
13. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S Cancer Lett; 2018 Jun; 423():36-46. PubMed ID: 29452146 [TBL] [Abstract][Full Text] [Related]
14. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma. Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317 [TBL] [Abstract][Full Text] [Related]
15. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer. Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330 [TBL] [Abstract][Full Text] [Related]
16. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737 [TBL] [Abstract][Full Text] [Related]
17. Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review). Li S; Hao L; Li N; Hu X; Yan H; Dai E; Shi X Int J Oncol; 2024 Sep; 65(3):. PubMed ID: 39092548 [TBL] [Abstract][Full Text] [Related]
18. LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma. Wu DM; Wang S; Wen X; Han XR; Wang YJ; Shen M; Fan SH; Zhang ZF; Shan Q; Li MQ; Hu B; Lu J; Chen GQ; Zheng YL Cell Death Dis; 2018 Sep; 9(10):947. PubMed ID: 30237435 [TBL] [Abstract][Full Text] [Related]
19. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Zhou D; Zhang Y; Wu H; Barry E; Yin Y; Lawrence E; Dawson D; Willis JE; Markowitz SD; Camargo FD; Avruch J Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1312-20. PubMed ID: 22042863 [TBL] [Abstract][Full Text] [Related]
20. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. Martin D; Degese MS; Vitale-Cross L; Iglesias-Bartolome R; Valera JLC; Wang Z; Feng X; Yeerna H; Vadmal V; Moroishi T; Thorne RF; Zaida M; Siegele B; Cheong SC; Molinolo AA; Samuels Y; Tamayo P; Guan KL; Lippman SM; Lyons JG; Gutkind JS Nat Commun; 2018 Jul; 9(1):2372. PubMed ID: 29985391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]